The impact of extended release dopamine agonists on prescribing patterns for therapy of early Parkinson's disease: An observational study

European Journal of Medical Research

Volumn 18, Issue 1, 2013, Pages

  Pellicano, Clelia ^a,b   Benincasa, Dario ^a,b,c   Fanciulli, Alessandra ^a,b   Latino, Pamela ^b   Giovannelli, Morena ^b   Pontieri, Francesco E ^a,b,c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

Dopamine agonists; Extended release; Levodopa; Parkinson's disease; Pramipexole; Ropinirole; Rotigotine

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; RASAGILINE;

AGED; ARTICLE; DAYTIME SOMNOLENCE; DISEASE SEVERITY; DOSE CALCULATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG FORMULATION; DRUG RELEASE; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL STATUS; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; OUTPATIENT CARE; PARKINSON DISEASE; PARKINSONISM; PRESCRIPTION; SUSTAINED DRUG RELEASE; UNIFIED PARKINSON DISEASE RATING SCALE; VISUAL HALLUCINATION; CLINICAL PRACTICE; DELAYED RELEASE FORMULATION; DEMOGRAPHY;

AGED; DELAYED-ACTION PREPARATIONS; DEMOGRAPHY; DOPAMINE AGONISTS; FEMALE; HUMANS; MALE; PARKINSON DISEASE; PHYSICIAN'S PRACTICE PATTERNS;

EID: 84890487122     PISSN: 09492321     EISSN: 2047783X     Source Type: Journal    
DOI: 10.1186/2047-783X-18-60     Document Type: Article

References (15)

1. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part 1: early (uncomplicated) Parkinson's disease. Horstink M, Tolosa E, Bonuccelli U, Deuschl G, Friedman A, Kanovsky P, Larsen JP, Lees A, Oertel W, Poewe W, Rascol O, Sampaio C, European Federation of Neurological Societies; Movement Disorder Society-European Section, Eur J Neurol 2006 13 1170 1185 10.1111/j.1468-1331.2006.01547.x 17038031 (Pubitemid 44581464)
2. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Deleu D, Northway MG, Hanssens Y, Clin Pharmacokinet 2002 41 261 309 10.2165/00003088-200241040-00003 11978145 (Pubitemid 34533757)
3. Role of dopamine receptor agonists in the treatment of early Parkinson's disease. Bonuccelli U, Del Dotto P, Rascol O, Parkinsonism Relat Disord 2009 15 Suppl 4 44 S53 20123557
4. The safety of dopamine agonists in the treatment of Parkinson's disease. Bonuccelli U, Ceravolo R, Expert Opin Drug Saf 2008 7 111 127 10.1517/14740338.7.2.111 18324875 (Pubitemid 351447695)
5. Continuous dopaminergic stimulation and novel formulations of dopamine agonists. Stocchi F, J Neurol 2011 258 Suppl 2 316 S322 21560062
6. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Giladi N, Boroojerdi B, Korczy AD, Burn DJ, Clarke CE, Schapira AHV, SP513 Investigators, Mov Disord 2007 22 2398 2404 10.1002/mds.21741 17935234 (Pubitemid 351155987)
7. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial. Poewe W, Rascol O, Barone P, Hauser RA, Mizuno Y, Haaksma M, Salin L, Juhel N, Schapira AH, Pramipexole ER Studies Group, Neurology 2011 77 759 766 10.1212/WNL.0b013e31822affb0 21832218
8. Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study. Stocchi F, Hersh BP, Scott BL, Nausieda PA, Giorgi L, Ease-PD Monotherapy Study Investigators, Curr Med Res Opin 2008 24 2883 2895 10.1185/03007990802387130 18768106
9. Treatment of patients with early and advanced Parkinson's disease with rotigotine transdermal system: age-relationship to safety and tolerability. Oertel W, LeWitt P, Giladi N, Ghys L, Grieger F, Boroojerdi B, Parkinsonism Relat Disord 2013 19 37 42 10.1016/j.parkreldis.2012.06.009 22954721
10. Therapy adherence issues in Parkinson's disease. Grosset D, European PD Therapy Compliance Study Group, J Neurol Sci 2010 289 115 118 10.1016/j.jns.2009.08.053 19793590
11. Diagnostic criteria for Parkinson's disease. Gelb DJ, Oliver E, Gilman S, Arch Neurol 1999 56 33 39 10.1001/archneur.56.1.33 9923759 (Pubitemid 29046907)
12. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Stacy M, Bowron A, Guttman M, Hauser R, Hughes K, Larsen JP, LeWitt P, Oertel W, Quinn N, Sethi K, Stocchi F, Mov Disord 2005 20 726 733 10.1002/mds.20383 15719426 (Pubitemid 41051784)
13. Switching dopamine agonists in advanced Parkinson's disease: Is rapid titration preferable to slow? Goetz CG, Blasucci L, Stebbins GT, Neurology 1999 52 1227 1229 10.1212/WNL.52.6.1227 10214748 (Pubitemid 29177926)
14. Efficacy and safety of extended- versus immediate-release pramipexole in Japanese patients with advanced and L-dopa-undertreated Parkinson disease: a double-blind, randomized trial. Mizuno Y, Yamamoto M, Kuno S, Hasegawa K, Hattori N, Kagimura T, Sarashina A, Rascol O, Schapira AH, Barone P, Hauser RA, Poewe W, Pramipexole ER Study Group, Clin Neuropharmacol 2012 35 174 181 10.1097/WNF.0b013e31825f77b9 22801294
15. Impact of recommendations on the initial therapy of Parkinson's disease: a population-based study in France. Fayard C, Bonaventure A, Benatru I, Roze E, Dumurgier J, Moisan F, Soumaré A, Houssinot J, Dupupet JL, Mazurie JL, Balaboi I, Houeto JL, Krim E, Ranoux D, Goldberg M, Imbernon E, Moreau T, Giroud M, Tzourio C, Elbaz A, Parkinsonism Relat Disord 2011 17 543 546 10.1016/j.parkreldis.2011.04.020 21612970